Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : WuXi XDC
Deal Size : Undisclosed
Deal Type : Collaboration
WuXi XDC & LigaChem Expand MOU to Boost ADC Development
Details : Through the collaboration, WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : WuXi XDC
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : DAAN Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
DAAN Biotherapeutics, LigaChem Partner on ADC Antibody Licensing Deal
Details : Under the licensing agreement, LigaChem will leverage DAAN Biotherapeutics' next-generation antibody technology for the treatment of solid tumor patients.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : DAAN Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Samsung Biologics Extends Collaboration with LigaChem Biosciences for ADC Development
Details : The collaboration will further strengthen LigaChem Biosciences capabilities across all stages of ADC development to treat solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Samsung Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : LCB97
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : $700.0 million
Deal Type : Licensing Agreement
Ono Inks $700M Biobuck Deal to Bag Preclinical LigaChem ADC
Details : Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97, a pre-clinical stage antibody-drug conjugate, for solid tumors.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : LCB97
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : $700.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2023
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LCB84
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AntibodyChem Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : LCB84
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AntibodyChem Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2022
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco
Deal Size : Inapplicable
Deal Type : Inapplicable
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2020
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco
Deal Size : Inapplicable
Deal Type : Inapplicable